Neo-adjuvant treatment of adenocarcinoma and squamous cell carcinoma of the cervix results in significantly different pathological complete response rates

Table 2 Primary treatment by tumor histology

Treatment, n (%)	AC	SCC	p
Surgery	10 (28)	23 (16)	0.169
Surgery + adjuvant chemoradiation^ab	12 (33)	36 (25)	0.437
Neo-adjuvant chemoradiation^a with intent for surgery^c	14 (39)	70 (49)	0.371
Definitive chemoradiation^ad	0 (0)	12 (8)	0.154
Brachytherapy alone^e	0 (0)	1 (1)	1
Neo-adjuvant chemotherapy + conization^f	0 (0)	1 (1)	1

AC adenocarcinoma (n = 36), SCC Squamous Cell Carcinoma (n = 143); ^a If possible, chemotherapy (C) was administered concomitantly and consisted of weekly single-agent cisplatin at 40 mg/m²; ^b In 11/33 AC/SCC patients this includes a brachytherapeutic boost; ^c 7 SCC patients did not receive surgery and 1/3 AC/SCC patients received a brachytherapeutic boost due to positive or doubtful margins; ^e due to co-morbidities; ^f fertility sparing

ISSN: 1471-2407